New HIV Frontier: The Fight To Access Long-Acting Prevention Drugs - Health Policy Watch

Last month, Médecins sans Frontières (MSF) launched a campaign to demand that the US-based Gilead “immediately make the highly effective HIV prevention

Brazilian Health Minister Dr Alexandre Padilha RIO DE JANEIRO – News that an antiretroviral drug injected twice a year had prevented almost all HIV infection in trials electrified the HIV sector two years ago – but access to Gilead’s lenacapavir has been slow, particularly for countries in Latin America. Brazil, which faces significant HIV transmission in certain groups, has been routinely excluded from HIV voluntary licensing deals offered by pharmaceutical companies – particularly for long-acting pre-exposure prophylaxis (PrEP) – as it is deemed an upper-middle-income country. Brazilian Heal

related reading

• FDA approves lenacapavir as a twice-a-year shot to prevent HIV | AP Newsapnews.com
• Hard Drugs | Lenacapavir: The miracle drug that could end AIDSharddrugs.worksinprogress.co
• Why we didn't get a malaria vaccine sooner - Works in Progress Magazineworksinprogress.co
• Grant for the support the development of MAP for self-administration of contraceptivesltslohmann.com
• Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
• Exploring the barriers to the antiretroviral therapy adherence among people living with HIV in Bangladesh: A qualitative approachpmc.ncbi.nlm.nih.gov
• Axmed - Accelerating Access to Medicines for Allaxmed.com
• How To Save Twenty Million Lives, with Dr. Mark Dybulstatecraft.pub
• Ophelia Dahl’s National Health Service | The New Yorkernewyorker.com
• Cure all diseasesworksinprogress.news
• The Ozempocalypse Is Nigh - by Scott Alexanderastralcodexten.com
• How Advocates Pushed Big Pharma to Cut Tuberculosis Drug Prices | Scientific Americanscientificamerican.com